Navigation Links
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
Date:9/25/2007

with or without an antibiotic."

Anthim(TM) Background

Anthim is high affinity monoclonal antibody that targets the protective antigen component of anthrax infection, blocking the bacteria's ability to form deadly toxins. It is being developed for prophylaxis and post-exposure treatment of inhalation anthrax. Anthim has been granted Fast Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs.

About Elusys' Heteropolymer Antibody(TM) Technology

HP Antibodies represent a new approach for the treatment of antibiotic resistant infections distinct from traditional therapies. HP Antibodies utilize natural immune system mechanisms to clear pathogens and provide a means to develop novel drug candidates targeted against bacterial, viral and fungal infections. By targeting a unique immune receptor, HP Antibodies enhance a natural clearance mechanism and direct the rapid removal of pathogens from the circulation to tissue macrophages. Elusys is currently working on novel approaches to the treatment of Staphylococcus and Candida infections using HP antibodies.

About Elusys

Elusys is a privately held biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of life- threatening infectious disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
9. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
10. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
11. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:8/29/2014)... August 29, 2014 Senior Independence ... operations & business development. , Rees has been with ... of business development. , A wholly owned subsidiary of ... provides older adults with options, including personalized home health ... (e.g., meal preparation) and therapeutic adult day centers. , ...
(Date:8/29/2014)... 29, 2014 Los Angeles dental ... mini implants to area patients. With this treatment, patients ... long-term teeth shifting and loss of appearance. Although mini ... implants , their smaller size allows for less ... easier recovery. Once placed, mini implants can be topped ...
(Date:8/29/2014)... A home should be a safe haven, but there ... Amica Insurance is sharing some tips to help improve safety in ... following safety measures: , Kitchen, , Store hazardous ... and keep them away from food. , ... , Bathroom , Put slip-resistant ...
(Date:8/29/2014)... life support (BLS) videos available on YouTube provide ... according to a new study published in ... Australasian College for Emergency Medicine (ACEM). , ... are known to improve survival for,victims. , A ... the study, which reviewed educational videos from the ...
(Date:8/29/2014)... Saturday 30 August 2014: New ESC registries ... coronary syndromes (ACS). The announcement comes as the ... and the study on heart failure patients conducted ... and Development (OECD) begins an outcomes evaluation. , ... EURObservational Research Programme (EORP). , Professor Roberto Ferrari, ...
Breaking Medicine News(10 mins):Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4
... ... of software & technology to Home Medical Equipment, Durable Medical Equipment, Respiratory ... a solution for each individual segment of Home Care as well as ... provider offering several or all of these product/service lines within one integrated ...
... ... interactive database on tap water quality. The data has been compiled from state environment ... concerning the database. , ... Washington (Vocus) December 11, 2009 -- On December 12, 2009, the Environmental Working ...
... 11 They feature real patients, real stories and ... campaign titled "Real Patients, Real Stories" won Platinum in ... event held in Chicago this fall. , Baylor teamed ... the non-traditional spots. The documentary-style ads feature actual patients ...
... sensory problems before onset of complex disease symptoms benefits ... -- Identifying sight and hearing problems in teens who ... doctors fully restore those senses and lessen the impact ... A new study found that problems in basic sensory ...
... A gene commonly studied by cancer researchers has been linked ... Understanding how the gene works means scientists may be ... a study by Texas AgriLife Research appearing in the Journal ... understand the mechanism, or how the gene works, we believe a ...
... The Visiting Nurse Association (VNA) of Greater Philadelphia is ... who reside in lower Bucks County. , The ... wound and ostomy care, and chronic care services. Nurses, ... to patients in their homes. , VNA also ...
Cached Medicine News:Health News:Fastrack Announces Enhancements to the Enterprise System for Home Care 2Health News:Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations 2Health News:Baylor Health Care System's Patient Testimonial Ad Campaign Wins National Award 2Health News:Early Treatment of Hearing, Vision Helps in Schizophrenia 2Health News:Study shows how gene action may lead to diabetes prevention, cure 2Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: